Jonathan Rubin, MD,MBA
Supernus Pharmaceuticals, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jonathan Rubin, MD,MBA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT04786990 · Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHDSupernus Pharmaceuticals, Inc. · completed · Attention-Deficit/Hyperactivity Disorder (ADHD)
- Ph3NCT02736656 · Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Supernus Pharmaceuticals, Inc. · active not recruiting · Attention-Deficit/Hyperactivity Disorder
- Ph2NCT00515437 · A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease PatientsSolstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC · completed · Drooling · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.